Drug: Furmonertinib

Phase 3Small molecule

Drug: Furmonertinib is one of 52 small molecule programs targeting Non-Small Cell Lung Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CarcinomaActive, not recruiting

Non-Small Cell Lung CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

80 competitors in Non-Small Cell Lung Carcinoma

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

6 2

Keytruda

Merck & Co.

Phase 3

5 3

Abraxane

Bristol-Myers Squibb

Phase 3

2 4

Dostarlimab

Incyte

Phase 3

1 5

Alecensa

Roche

Phase 3

1 6

Plavix

Sanofi

Phase 3

1 7

Paraplatin

AAvyxa

Phase 3

7 8

DATROWAY

Cabometyx

Alimta

EEagle Vision Pharmaceutical Corp.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 3Recruiting

Non-Small Cell Lung Carcinoma

NCT04853342

Clinical

Trials by Indication[1]

Non-Small Cell Lung Carcinoma1 trial

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Recruiting·AAllist Pharmaceuticals, Inc.·Phase 3·NCT04853342·318 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug: Furmonertinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug: Furmonertinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug: Furmonertinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Allist Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAllist Pharmaceuticals, Inc.

Drug: Furmonertinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Non-Small Cell Lung Carcinoma1 trial

References

Drug Info

Quick Facts

Related News